JP2017519821A5 - - Google Patents

Download PDF

Info

Publication number
JP2017519821A5
JP2017519821A5 JP2017518397A JP2017518397A JP2017519821A5 JP 2017519821 A5 JP2017519821 A5 JP 2017519821A5 JP 2017518397 A JP2017518397 A JP 2017518397A JP 2017518397 A JP2017518397 A JP 2017518397A JP 2017519821 A5 JP2017519821 A5 JP 2017519821A5
Authority
JP
Japan
Prior art keywords
group
alkyl
membered
alkyl group
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017518397A
Other languages
English (en)
Japanese (ja)
Other versions
JP6680774B2 (ja
JP2017519821A (ja
Filing date
Publication date
Priority claimed from CN201410271282.9A external-priority patent/CN105461711B/zh
Application filed filed Critical
Priority claimed from PCT/CN2015/081518 external-priority patent/WO2015192760A1/zh
Publication of JP2017519821A publication Critical patent/JP2017519821A/ja
Publication of JP2017519821A5 publication Critical patent/JP2017519821A5/ja
Application granted granted Critical
Publication of JP6680774B2 publication Critical patent/JP6680774B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017518397A 2014-06-17 2015-06-16 PI3K阻害剤としてのピリド[1,2−a]ピリミドン類似体 Active JP6680774B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201410271282.9 2014-06-17
CN201410271282.9A CN105461711B (zh) 2014-06-17 2014-06-17 作为PI3K抑制剂的吡啶并[1,2-a]嘧啶酮类似物
CN201510324348 2015-06-12
CN201510324348.0 2015-06-12
PCT/CN2015/081518 WO2015192760A1 (zh) 2014-06-17 2015-06-16 作为pi3k抑制剂的吡啶并[1,2-a]嘧啶酮类似物

Publications (3)

Publication Number Publication Date
JP2017519821A JP2017519821A (ja) 2017-07-20
JP2017519821A5 true JP2017519821A5 (enExample) 2018-06-28
JP6680774B2 JP6680774B2 (ja) 2020-04-15

Family

ID=54934872

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017518397A Active JP6680774B2 (ja) 2014-06-17 2015-06-16 PI3K阻害剤としてのピリド[1,2−a]ピリミドン類似体

Country Status (11)

Country Link
US (1) US9856256B2 (enExample)
EP (1) EP3159341B8 (enExample)
JP (1) JP6680774B2 (enExample)
KR (1) KR102495840B1 (enExample)
CN (1) CN106470992B (enExample)
AU (1) AU2015276699B2 (enExample)
CA (1) CA2951971C (enExample)
EA (1) EA032642B1 (enExample)
ES (1) ES2754264T3 (enExample)
TW (1) TWI628180B (enExample)
WO (1) WO2015192760A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10479789B2 (en) * 2015-12-16 2019-11-19 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pyrido[1,2-A]pyrimidone analog, crystal form thereof, intermediate thereof and preparation method therefor
CN110386932A (zh) 2018-04-20 2019-10-29 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
CN113316575B (zh) * 2019-01-24 2022-03-18 江苏奥赛康药业有限公司 作为TGF-βR1激酶抑制剂的5-(4-吡啶氧基)吡唑类化合物
CN115151540A (zh) 2019-12-02 2022-10-04 风暴治疗有限公司 作为mettl3抑制剂的多杂环化合物
EP4095137A4 (en) * 2020-02-10 2024-03-13 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. USE OF A PYRIDO[1,2-A]PYRIMIDINONE COMPOUND FOR THE TREATMENT OF LYMPHOMAS
US20230119759A1 (en) 2020-03-10 2023-04-20 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pharmaceutical combination comprising pyridino[1,2-a]pyrimidinone compound
CN116323609B (zh) * 2020-09-15 2026-02-24 正大天晴药业集团股份有限公司 吡啶并[1,2-a]嘧啶酮化合物的治疗外周T细胞淋巴瘤的用途
CN116761608A (zh) * 2020-12-08 2023-09-15 正大天晴药业集团股份有限公司 吡啶并[1,2-a]嘧啶酮化合物的治疗妇科肿瘤的用途
CN118510518A (zh) * 2022-03-09 2024-08-16 正大天晴药业集团股份有限公司 包括吡啶并[1,2-a]嘧啶酮化合物和EGFR抑制剂的药物组合

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1678180B1 (en) * 2003-10-10 2007-08-08 Pfizer Products Incorporated Substituted 2h-[1,2,4]triazolo 4,3-a pyrazines as gsk-3 inhibitors
EP2038272B8 (en) * 2006-06-30 2013-10-23 Sunesis Pharmaceuticals, Inc. Pyridinonyl pdk1 inhibitors
JP2011500823A (ja) * 2007-10-22 2011-01-06 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Pi3キナーゼ阻害物質としてのピリドスルホンアミド誘導体
JP5599783B2 (ja) * 2008-05-30 2014-10-01 アムジエン・インコーポレーテツド Pi3キナーゼの阻害薬
WO2012003392A1 (en) * 2010-07-02 2012-01-05 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
WO2012037108A1 (en) * 2010-09-13 2012-03-22 Glaxosmithkline Llc Aminoquinoline derivatives as antiviral agents
JP5820080B2 (ja) * 2011-11-17 2015-11-24 山▲東▼▲軒▼竹医▲葯▼科技有限公司 三環系PI3K及び/又はmTOR抑制剤
CN103539777B (zh) * 2012-07-13 2016-03-02 广东东阳光药业有限公司 Pi3激酶调节剂及其使用方法和用途
WO2014022128A1 (en) * 2012-07-29 2014-02-06 Calitor Sciences, Llc Pi3 kinase modulators and methods of use
TW201443037A (zh) * 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
BR112016029825B1 (pt) * 2014-06-17 2020-10-27 Cisen Pharmaceutical Co., Ltd. composto

Similar Documents

Publication Publication Date Title
JP2015516427A5 (enExample)
JP2012092103A5 (enExample)
JP2016515560A5 (enExample)
JP2016121196A5 (enExample)
JP2018531218A5 (enExample)
JP2009531322A5 (enExample)
JP2016540742A5 (enExample)
JP2016540028A5 (enExample)
JP2018537413A5 (ja) 化合物、医薬的に許容される塩又はその立体異性体及び医薬組成物
RU2020131276A (ru) Терапевтические соединения и композиции
JP2016503797A5 (enExample)
JP2018526405A5 (enExample)
JP2017526674A5 (enExample)
AR095423A1 (es) 2-azabiciclos sustituidos y su uso como moduladores del receptor de orexina
JP2015505296A5 (enExample)
JP2012513416A5 (enExample)
JP2016540809A5 (enExample)
JP2020507589A5 (enExample)
JP2015504081A5 (enExample)
JP2020505400A5 (enExample)
JP2015051983A5 (enExample)
JP2018197343A5 (enExample)
JP2019527233A5 (enExample)
JP2015524019A5 (enExample)
JP2018197257A5 (enExample)